Muscular dystrophy treatment success

Israel’s BioBlast announced promising interim results from its Phase II study of its Cabaletta treatment for oculopharyngeal muscular dystrophy (OPMD). Due to the success BioBlast seeks to fast track a Phase III study in 2016, leading to a 2017 launch date.

http://www.globes.co.il/en/article-bioblast-orphan-drug-gives-hope-to-opmd-patients-1001076594

 

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.